{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:34:40Z","timestamp":1726014880865},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Stroke, as a type of cardiovascular disease (CVD) and cerebrovascular disease, has the risk of causing death or disability in patients. Aspirin, as an antipyretic and analgesic drug, can also treat or prevent CVDs. Previous studies have had conflicting results on the preventive effect of aspirin on cerebral infarction for patients with CVD risk factors. This review was carried out through a meticulous search of the Web of Science and PubMed databases. Articles were included or excluded based on predefined criteria. In terms of heterogeneity, a fixed effect model was utilized when <jats:italic toggle=\"yes\">I<\/jats:italic>\n                           <jats:sup>2<\/jats:sup> was less than 50%. Conversely, if the studies were deemed clinically comparable, a random effect model was implemented. The findings suggest that medical intervention significantly mitigates the risk of cerebral infarction in patients predisposed to CVDs [odds ratio (OR), 0.85; 95% confidence interval (CI), 0.74\u20130.98; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03]. Interestingly, the preventive efficacy of medication appears to be higher in men (OR, 0.82; 95% CI, 0.72\u20130.94; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004) than in women (OR, 0.84; 95% CI, 0.69\u20131.01; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.06). However, in terms of stroke prevention, no significant difference was observed between the use of aspirin (OR, 0.90; 95% CI, 0.76\u20131.06; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.19) and other medications (OR, 0.65; 95% CI, 0.31\u20131.38; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.26).<\/jats:p>","DOI":"10.1097\/crd.0000000000000778","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:23:14Z","timestamp":1725981794000},"update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic Effect of Aspirin and Other Medicine on Cerebral Infarction for Patients with Cardiovascular Diseases Risk Factors: A Systemic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Binfei","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Neurorehabilitation, Zhejiang Rehabilitation Medical Center, Rehabilitation Hospital Area of the Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijiang","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation, Zhejiang Rehabilitation Medical Center, Rehabilitation Hospital Area of the Third Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"R2-20240910","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41569-021-00607-3","article-title":"Epidemiology of cardiovascular disease in Europe.","volume":"19","author":"Townsend","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"1, Part 2","key":"R4-20240910","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles.","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"key":"R5-20240910","first-page":"E240","article-title":"Heart disease and stroke statistics-2011 update: a report from the American Heart Association (vol 123, pg e18, 2011).","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"R6-20240910","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/STR.0b013e31829734f2","article-title":"Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association.","volume":"44","author":"Ovbiagele","year":"2013","journal-title":"Stroke"},{"key":"R7-20240910","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCRESAHA.116.308398","article-title":"Stroke risk factors, genetics, and prevention.","volume":"120","author":"Boehme","year":"2017","journal-title":"Circ Res"},{"key":"R8-20240910","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11883-011-0187-y","article-title":"Impact of hypertension on stroke.","volume":"13","author":"Dubow","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"R9-20240910","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"R10-20240910","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R11-20240910","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol"},{"key":"R12-20240910","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/STROKEAHA.111.641381","article-title":"Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study.","volume":"43","author":"Banerjee","year":"2012","journal-title":"Stroke"},{"key":"R13-20240910","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/diacare.28.2.355","article-title":"Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati\/Northern Kentucky Stroke Study.","volume":"28","author":"Kissela","year":"2005","journal-title":"Diabetes Care"},{"key":"R14-20240910","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1098\/rstl.1763.0033","article-title":"XXXII. An account of the success of the bark of the willow in the cure of agues. In a letter to the Right Honourable George Earl of Macclesfield, President of R. S. from the Rev. Mr. Edward Stone, of Chipping-Norton in Oxfordshire.","volume":"53","author":"Stone","year":"1763","journal-title":"Philos Trans R Soc London"},{"key":"R15-20240910","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.","volume":"2","year":"1988","journal-title":"Lancet"},{"issue":"6 Pt 2","key":"R16-20240910","first-page":"V79","article-title":"The aspirin myocardial infarction study: final results.","volume":"62","year":"1980","journal-title":"Circulation"},{"issue":"6 Pt 2","key":"R17-20240910","first-page":"V59","article-title":"Aspirin in coronary heart disease.","volume":"62","year":"1980","journal-title":"Circulation"},{"key":"R18-20240910","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.","volume":"1","author":"Elwood","year":"1974","journal-title":"Br Med J"},{"key":"R19-20240910","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(79)92808-3","article-title":"Aspirin and secondary mortality after myocardial infarction.","volume":"2","author":"Elwood","year":"1979","journal-title":"Lancet"},{"key":"R20-20240910","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"R21-20240910","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1188\/15.ONF.552-554","article-title":"Preferred reporting items for systematic reviews and meta-analyses.","volume":"42","author":"Vrabel","year":"2015","journal-title":"Oncol Nurs Forum"},{"key":"R22-20240910","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/HJH.0000000000002034","article-title":"Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.","volume":"37","author":"Ando","year":"2019","journal-title":"J Hypertens"},{"key":"R23-20240910","doi-asserted-by":"crossref","first-page":"e014726","DOI":"10.1161\/JAHA.119.014726","article-title":"Influence of sex on platelet reactivity in response to aspirin.","volume":"9","author":"Friede","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R24-20240910","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11883-008-0053-8","article-title":"Stroke prevention in women: challenges and opportunities.","volume":"10","author":"Bushnell","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"R25-20240910","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70).","volume":"19","author":"Sugawara","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"R26-20240910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"R27-20240910","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/VHRM.S266968","article-title":"Ticagrelor use in stroke patients: past, present, and future.","volume":"17","author":"Chandra","year":"2021","journal-title":"Vasc Health Risk Manag"},{"key":"R28-20240910","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"R29-20240910","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\"AICLA\" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"key":"R30-20240910","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1161\/01.CIR.92.8.2178","article-title":"Silent cerebral infarction in patients with nonrheumatic atrial fibrillation.","volume":"92","author":"Ezekowitz","year":"1995","journal-title":"Circulation"},{"key":"R31-20240910","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/jamacardio.2022.0480","article-title":"Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE\u2013AF Randomized Clinical Trial.","volume":"7","author":"Kuroda","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R32-20240910","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"R33-20240910","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"R34-20240910","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus.","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"R35-20240910","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update.","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"R37-20240910","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.jacc.2007.11.080","article-title":"The role of aspirin in cardiovascular prevention.","volume":"51","author":"Gasparyan","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R38-20240910","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus.","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"R39-20240910","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association.","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"R40-20240910","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1741-7015-5-29","article-title":"The influence of gender on the effects of aspirin in preventing myocardial infarction.","volume":"5","author":"Yerman","year":"2007","journal-title":"BMC Med"},{"key":"R41-20240910","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","article-title":"Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics.","volume":"14","author":"Anderson","year":"2005","journal-title":"J Womens Health (Larchmt)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T15:23:41Z","timestamp":1725981821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000778","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}